Most potent IV bisphosphonate — once-yearly infusion for osteoporosis (Reclast) or every 3-4 weeks for malignancy-related bone lesions / hypercalcemia of malignancy (Zometa). Acute-phase reaction + osteonecrosis of jaw + atypical femoral fractures are class concerns at chronic use.
Half-Life (t½)
IV: 39h
Dosing Guidelines
IV: Typical 5 mg (Range: 4–5 mg)
Target Organ Systems
musculoskeletal
Pathways It Modulates
Bone remodeling (inhibitor) — osteoclast farnesyl-PP synthase